S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
MSFT   168.07 (-1.65%)
CGC   19.62 (-3.35%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
AMD   47.57 (-3.16%)
ACB   1.51 (-2.58%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
MSFT   168.07 (-1.65%)
CGC   19.62 (-3.35%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
AMD   47.57 (-3.16%)
ACB   1.51 (-2.58%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
MSFT   168.07 (-1.65%)
CGC   19.62 (-3.35%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
AMD   47.57 (-3.16%)
ACB   1.51 (-2.58%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
MSFT   168.07 (-1.65%)
CGC   19.62 (-3.35%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
AMD   47.57 (-3.16%)
ACB   1.51 (-2.58%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:PRAN - Prana Biotechnology Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.06
+1.33 (+182.27 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$2.06
Now: $2.06
$2.06
50-Day Range
$0.95
MA: $1.41
$2.06
52-Week Range
$1.09
Now: $2.06
$2.91
VolumeN/A
Average Volume130,956 shs
Market Capitalization$18.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAN
CUSIPN/A
Phone61-3-9349-4906

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$1.40 per share

Profitability

Miscellaneous

Employees14
Market Cap$18.33 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PRAN News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.


Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions

What is Prana Biotechnology's stock symbol?

Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."

Has Prana Biotechnology been receiving favorable news coverage?

News headlines about PRAN stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Prana Biotechnology earned a news impact score of -3.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Prana Biotechnology.

Who are some of Prana Biotechnology's key competitors?

What other stocks do shareholders of Prana Biotechnology own?

Who are Prana Biotechnology's key executives?

Prana Biotechnology's management team includes the folowing people:
  • Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)
  • Ms. Kathryn Andrews, Chief Financial Officer (Age 52)
  • Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)
  • Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory Board
  • Dr. Steven D. Targum M.D., Chief Medical Advisor

What is Prana Biotechnology's stock price today?

One share of PRAN stock can currently be purchased for approximately $2.06.

How big of a company is Prana Biotechnology?

Prana Biotechnology has a market capitalization of $18.33 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe.View Additional Information About Prana Biotechnology.

What is Prana Biotechnology's official website?

The official website for Prana Biotechnology is http://www.pranabio.com/.

How can I contact Prana Biotechnology?

Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]


MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  184 (Thanks for Voting!)
Underperform Votes:  265 (Thanks for Voting!)
Total Votes:  449
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Support Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel